DR info

臨床試験数 : 5 / 薬物数 : 13 - (DrugBank : 6) / 標的遺伝子数 : 13 - 標的パスウェイ数 : 25

薬物ごとの開発者（Primary Sponsor）、臨床試験情報（抜粋）です。

Carbidopa-levodopa
   Washington University School of Medicine
      2019   Phase 1   NCT03929068   United States;
Dalfampridine
   Weill Medical College of Cornell University
      2016   Phase 1   NCT02868567   United States;
Daraprim
   Weill Medical College of Cornell University
      2013   -   EUCTR2011-004798-99-DE   Germany;Italy;United States;
Dexdor
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland;
HB-adMSCs
   Hope Biosciences Stem Cell Research Foundation
      2021   -   NCT04825613   United States;
Ketanest-S
   Turku University Hospital
      2018   Phase 4   EUCTR2018-000142-18-FI   Finland;
Levetiracetam
   Duke University
      2006   Phase 2   NCT00324454   United States;
Stem Cells
   Stem Cells Arabia
      2016   Phase 1/Phase 2   NCT03067857   -